INTRODUCTION
Africa is a region with the highest prevalence of glaucoma (1, 2) , and most patients present with advanced stage of the disease or unilateral blindness with high intraocular pressure (IOP) (3). Glaucoma filtration procedures (Trabeculectomy) are commonly required for IOP control and preservation of vision. The African race is also associated with higher rate of failure of trabeculectomy (4) . It is always a challenge for ophthalmologists in the region in dealing with such failed cases of trabeculectomy and other complex secondary glaucomas.
Glaucoma drainage devices (GDD) are generally used for such refractory cases where conventional surgery has failed or is likely to fail; these also include uveitic glaucoma, neovascular glaucoma, previous ocular surgery or other conditions associated with conjunctival scarring. The plates of glaucoma implants offer a large surface area reservoir for the drainage of aqueous humor and prevent excessive scar tissue formation at the limbus (5) .
GDD include the open tube drainage devices like Molteno implant, the Baerveldt implant and the Schocket tube shunt, and the flow-restrictive drainage devices like the Krupin and the Ahmed Glaucoma Valve (AGV) implants (6) . Restrictive devices contain a valve that is designed to reduce the incidence of postoperative hypotony, while offering the benefit of immediate pressure reduction. The AGV is being widely used throughout the world since its introduction in 1993 (7).
There is a scarcity of data on the outcome of GDD surgery in Africa. Studying the outcomes of these types of surgeries is important as a quality control and to compare results with experience in other areas. It will also serve as a baseline for future interventions.
In a retrospective case series investigating, the outcomes of AGV among 25 eyes of children and adult patients in Kenya, Kiage et al reported 79% success and 53.3% mean IOP reduction at 2 a months' follow-up (8) . A recent retrospective review of 13 eyes of 12 patients who underwent this surgery in Central Ethiopia showed a success rate of IOP controlling of 76.9% (9) . The current study was carried out to describe the initial experience of AGV implant surgery in a tertiary hospital in Southwest Ethiopia.
PATIENTS AND METHODS
This is a retrospective review of the medical records of patients with refractory glaucoma who underwent isolated tube shunt surgery using AGV in the Department of Ophthalmology, Jimma University Specialized Hospital, between August 2012 and August 2014. Patients who had completed postoperative follow-up of 6 months and for whom IOP was taken at baseline and during the follow-up period were included. All eyes had glaucoma, which could not be controlled by medications and/or previous glaucoma surgery. The diagnosis of glaucoma was based on the IOP, characteristic optic nerve pathology with or without visual field changes.
A predesigned format was used to retrieve clinical information from the charts which included age and sex of the patients, type of glaucoma, previous ocular surgery, current surgical procedure and pre-and post-operative visual acuity (VA), IOP and glaucoma medications. IOP was measured using Goldman applanation tonometer mounted on slit lamp or iCare rebound tonometer (iCare Finland, Helsinki, Finland). Postoperative IOP taken at 1 st week as well as 1 st , 2 nd and 6 th month postoperative periods were included. Any intraoperative and postoperative complication was also noted. The clinical data was collected by a senior ophthalmology resident in the department and the author; all surgical procedures were performed by the same surgeon (GG). Surgical method: General steps followed in the procedure are described elsewhere (6) . In this series, AGV consisting of a silicone tube connected to a silicone reservoir plate (FP7 or FP8 models) [New World Medical Inc., Rancho Cucamonga, California] was used (6) . Model FP7 with large surface area of 184 mm 2 was inserted in 11 eyes and model FP8 with surface area of 96mm 2 in 1 eye. Surgery was performed using retro-bulbar or sub-tenon anesthesia. AGV was implanted in the upper temporal fornix in all cases, 9-0 nylon was used to suture the implant to the sclera, and either human sclera or cornea was used to cover the tube near the limbus. Definition of success and failure: The primary outcome variable for success was postoperative IOP control in 6 months, i.e. IOP less than 22mmHg and more than 5mmHg with at least 30% reduction from the preoperative level in the absence of devastating ocular complications. Eyes that met the above criteria and were not on supplemental anti-glaucoma medical therapy were defined as complete successes and those that met the criteria either with or without supplemental medical therapy were defined as qualified successes. Hypotony was defined as IOP less than or equal to 5mm Hg on any post-operative visit. Hypertensive phase (HP) was defined as an IOP measurement of greater than 21mmHg (with or without medications) during the 6-month postoperative period that was not a result of tube obstruction, retraction or malfunction. Resolution of this phase was IOP of less than 22mmHg along with a reduction of the IOP by 3mmHg or more with the same or less number of medications (10) . Cataract was considered to have progressed if there was loss of 2 lines of Snellen VA that was attributed to cataract at the six-month follow-up visit.
Clinical data was analyzed using SPSS software for Windows Version 16 (IBM Corp., New York, NY, USA). Simple descriptive statistics (frequency, mean, percentage) were used to describe the study variables. The difference of the mean postoperative IOP was compared from baseline level using student's t-test. Due to the sample size,advanced statistical methods are not used to look for possible factors associated with success and failure of the procedure. Ethical clearance: The study was done with adherence to the guidelines of the Declaration of Helsinki. Ethical clearance was obtained from the Department of Ophthalmology, College of Public Health and Medical Sciences, Jimma University. As part of our routine practice, patients provided 
RESULTS
A total of 19 eyes of 18 patients underwent AGV implant surgery during the specified period. Two patients (2 eyes) who did not have follow-up beyond the first postoperative month and 2 children (3 eyes) (less than 4 years of age) were excluded. Two charts could notbe retrieved. Therefore, data of 12 eyes of 11 patients were included in this study.
The mean age of patients was 40.7 (SD = 19.0) years (range = 12-67 years); 63.6% were males. The most common diagnosis was pseudoexfoliative glaucoma (3 eyes) followed by uveitic glaucoma, Juvenile Open Angle Glaucoma (JOAG) and chronic angle closure glaucoma (2 eyes each).
Primary Open Angle Glaucoma (POAG), traumatic and silicone oil induced glaucoma were diagnosed in 1 eye each. About 75% of eyes had advanced glaucoma with vertical cup-disc ratio of 0.85 and above; and 83% of eyes had one or more intraocular surgery or laser treatment performed before the current implant, the average being 1.58 per eye (see table 1 ). The types of glaucoma medication used included: Timolol 0.5%, Pilocarpine 4%, Latanoprost 0.005% (Xalatan), Bimatoprost 0.03% (Lumigan) and oral Acetazolamide.
The mean (SD) preoperative IOP was 32.75(7.14) mmHg, the mean IOP at 6 month was 15.75 (4.35) mmHg, with 51.9% reduction from baseline. This was statistically significant (P<0.001). The mean postoperative IOP was lower than the baseline level for all individual postoperative periods; 9.36(4.41), 15.58(7.18), 16 .36(4.78) and 15.75(4.35) at first the week, first, second and 6 th months respectively (see Fig 1 and  table 2 ). According to the study definition, 8/12 eyes (66.7%) had complete success while 10/12 eyes (83.3%) had qualified success at 6 month. The mean number of medications was reduced from 2.1 preoperatively to 0.33 at 6 month, with the use of acetazolamide tablets reduced from 72.7% to 0. 
DISCUSSION
The probability of success of AGV implant surgeries reported in the literature varies due to differences in definition of success rate, in the follow-up period, the surgical technique, the type of implant used and the study population (particularly the glaucoma types).
In the present study, the mean IOP was reduced by 51.9% from the baseline of 32.75 ±7.14 to 15.75 ± 4.35 at 6 month; 8/12 eyes (66.7%) had complete successes while 10/12 eyes (83.3%) had qualified success. This is in agreement with outcomes reported in the literature. A success rate of 76.9% at 6 month was reported in another study from Ethiopia (9),while a 79% success in a 2 months' follow-up has been reported among patients from Kenya
The Ahmed Glaucoma Valve Girum W. Gessesse Cerebral Vein Thrombosis Feridoun S. et al 271 (using iCare and Goldman applanation tonometers) (8) . A cumulative probability of success ranging from 66% -94% at 12 month has also been reported from Asia and other regions of the world (5, (11) (12) (13) (14) . The efficacy of a glaucoma surgery in reducing IOP must be interpreted in the context of its adverse events, with evaluation of the incidence and severity of associated complications (15) . In our series, intraoperative and postoperative complications were encountered in 2/12(16.7%) and 5/12(41.7%) eyes respectively; acceleration of cataract, hypotony, choroidal effusion and tube iris touch are among the commonly reported postoperative complications.
No major complications related with tube (erosion, exposure, corneal touch) or devastating ocular complications, requiring secondary intervention, were also encountered. The visual deterioration observed in two eyes was explained by the progression of cataract. The overall intraoperative complication rate reported from the Ahmed Baerveldt Comparison (ABC) study was 10% (16) . In the Ahmed Versus Baerveldt study (17) and the ABC Study, 45% and 43% of patients in the AGV arm/group experienced postoperative complications respectively. Complications reported in these studies were similar to those we encountered in our series. Three eyes had improvement of two lines or more of VA, and this is explained by clearing of corneal edema postoperatively in all cases.
Following GDD surgeries, a hypertensive phase (HP) can develop between 4 and 16 weeks postoperatively, during which IOP may rise into the high 20s or 30s (10) . HP was diagnosed in 2/12(16.6%) of our series, at the 1 st and third months postoperatively. This is similar to a reported prevalence of 15.8% and 18.4% of patients in AGV group at the 3 rd and 6 th months respectively (18) , while it has been identified in up to 63.2% of patients (10, 19) . On the other hand, some studies did not find this hypertensive phase (5), including series of patients with uveitic glaucoma (12) . The AGV is said to be associated with a higher incidence of the HP, which peaked at the 1 st month and stabilized by 6 months after the operation (20) (21) . This course goes in line with our experience.
It has been hypothesized that the implant type, material and surface area may affect the degree of IOP reduction, with a small retrospective comparison suggesting that the FP7model lower IOP more than the S2 model does (22) , and a review of implants shows that large end plates achieve greater pressure reduction (23) . While we used implants with silicone tubes and plates for all of our patients and the only eye that received the small surface area FP8 model in our series is in the failure group, it is difficult to compare this with other studies or between groups due to small number of eyes studied.
The major limitation of this study is the small sample size and the short period of follow-up. Post-operative follow-up as well as follow-ups to prescribed medications are well-recognized problems in most parts of Africa (24) . It can also be said that in such cases where patient follow-up and compliance is a concern, the AGV may have been wiser options to preserve vision due to a lesser rate of early post-operative complications and need for post-operative interventions (25) . Despite these, we hope that this study reflects one arm of African experience on this novel surgical intervention.
In conclusion, Ahmed Glaucoma Valve implantation appears to be a safe and effective modality of treatment for complicated glaucoma in Ethiopians with an overall success at early stages comparable to those reported from other studies.
